The effect of bicarbonate peritoneal dialysis solutions on cardiac structural and functional alterations

Nephrology Dialysis Transplantation

Volumn 26, Issue 12, 2011, Pages 4061-4067

  Theodoridis, Marios ^a   Tziakas, Dimitrios ^a   Passadakis, Ploumis ^a   Kantartzi, Konstantia ^a   Roumeliotis, Athanasios ^a   Thodis, Elias ^a   Vargemezis, Vassilis ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

bicarbonate solutions; left ventricle ejection fraction; left ventricle mass index; peritoneal dialysis

Indexed keywords

BICARBONATE; GLYOXAL; LACTIC ACID; PERITONEAL DIALYSIS FLUID;

ADULT; AGED; ARTICLE; BIOCOMPATIBILITY; CARDIOVASCULAR MALFORMATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEART VENTRICLE SIZE; HUMAN; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TISSUE STRUCTURE; TREATMENT DURATION; ULTRAFILTRATION; URINE VOLUME;

AGED; BICARBONATES; FEMALE; HEART; HEMODIALYSIS SOLUTIONS; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PROSPECTIVE STUDIES;

EID: 82255181472     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr206     Document Type: Article

References (15)

1. Linden T, Cohen A, Deppisch R et al. 3,4-dideoxyglucosone-3-ene (3,4-DGE): A cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int 2002; 62: 697-703 (Pubitemid 34779784)
2. Nakayama M, Kawaguchi Y, Yamada K et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51: 182-186 (Pubitemid 27064536)
3. Schwenger V, Morath C, Salava A et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17: 199-207
4. Kihm LP, Wibisono D, Muller-Krebs S et al. RAGE expression in the human peritoneal membrane. Nephrol Dial Transplant 2008; 23: 3302-3306
5. Welten AG, Schalkwijk CG, ter Wee PM et al. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Perit Dial Int 2003; 23: 213-221 (Pubitemid 37045656)
6. Zeier M, Schwenger V, Deppisch R et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63: 298-305 (Pubitemid 35463934)
7. Muller-Krebs S, Kihm LP, Zeier B et al. Renal toxicity mediated by glucosedegradation products in a rat model of advanced renal failure. Eur J Clin Invest 2008; 38: 296-305 (Pubitemid 351489911)
8. Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458 (Pubitemid 16119719)
9. Bloembergen WE, Port FK, Mauger EA et al. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1995; 6: 177-183
10. Jaar BG, Coresh J, Plantinga LC et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 2005; 143: 174-183
11. Schwenger V, Morath C, Salava A et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17: 199-207
12. Zeier M, Schwenger V, Deppisch R et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63: 298-305 (Pubitemid 35463934)
13. Lee HY, Park HC, Seo BJ et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (balance). Perit Dial Int 2005; 25: 248-255 (Pubitemid 40724205)
14. Lee HY, Choi HY, Park HC et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 2006; 21: 2893-2899 (Pubitemid 44542247)
15. Tomo T. Peritoneal dialysis solutions low in glucose degradation products-evidence for clinical benefits. Perit Dial Int 2008; 28 (Suppl 3): S123-S1237